Cas:18627-38-8 n-dodecanoyl-dl-homoserine lactone manufacturer & supplier

We serve Chemical Name:n-dodecanoyl-dl-homoserine lactone CAS:18627-38-8 to global customers since 2007, Pls send inquiry to info@nbinno.com or visit www.nbinno.com our official website should you have any interests. This site is for information only.

n-dodecanoyl-dl-homoserine lactone

Chemical Name:n-dodecanoyl-dl-homoserine lactone
CAS.NO:18627-38-8
Synonyms:N-dodecanoyl-HSL;N-dodecanoyl-DL-homoserine;3-dodecanoylamino-dihydro-furan-2-one;n-lauroyl-dl-homoserine lactone;N-Dodecanoyl-DL-homoserine lactone;N-dodecanoyl-homoserine lactone
Molecular Formula:C16H29NO3
Molecular Weight:283.40600
HS Code:2932209090

Physical and Chemical Properties:
Melting point:N/A
Boiling point:N/A
Density:N/A
Index of Refraction:
PSA:55.40000
Exact Mass:283.21500
LogP:3.72990

Material Safety Information (Applicable for Hazard Chemicals)
RIDADR:NONH for all modes of transpor
Packing Group:


Contact us for information like N-dodecanoyl-HSL chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-dodecanoyl-homoserine lactone physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-dodecanoyl-DL-homoserine Use and application,n-lauroyl-dl-homoserine lactone technical grade,usp/ep/jp grade.


Related News: “The Delta variant is clearly circulating, and it’s more contagious, and it seems to be causing more disease,” said ACIP member Katherine Poehling, M.D., an epidemiologist at Wake Forest School of Medicine. 2-Bromo-5-pyrimidinecarbonitrile manufacturers Stevanato’s been out of start-up mode for a while: The firm doubled its net profit to $94 million in 2020 on $779 million in revenues, which were up 23% from 2019. That strong growth in sales helped place Sergio Stevanato, 79, Giovanni’s son and the company’s chairman emeritus, on Forbes’ World’s Billionaires list for the first time in 2021, with a net worth of $1.9 billion. 5-nonyloxytryptamine suppliers Though the program obtained priority review from FDA back in November, analysts expressed skepticism in July 2020 after it failed to prove superior to the companies’ other drug Lumizyme in improving respiratory function in a Phase III trial. 6-chloro-2-methylquinolin-4-amine vendor & factory.